Full Press Release Details
MILFORD, Mass. , Aug. 1, 2023 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) introduced the first in a new line of size exclusion chromatography (SEC) columns aimed at improving the analysis while lowering the cost of gene therapies, specifically adeno-associated viral (AAV) vectors. The new Waters™ XBridge™ Premier GTx BEH™ SEC columns doubles the speed of measuring the potency and safety of AAVs. Combining the columns with light scattering technologies from its Wyatt Technology portfolio deepens the level of information acquired from a single experiment and optimizes the manufacturing of these novel gene delivery vehicles.
Waters' new chromatography columns are aimed at improving the analysis while lowering the cost of gene therapies
"We are witnessing a revolution in medicine thanks to gene therapies like AAVs," said Erin Chambers , Vice President, Consumables and Lab Automation, Waters Corporation. "A small quantity of a gene therapy, such as one of the best-selling eye treatments, can retail for more than $400,000 per eye iii . This makes it imperative that process and formulation development tests measure multiple attributes of the drug at once while consuming as little of it as possible. It's why Waters' low adsorption, high-efficiency XBridge Premier GTx BEH SEC columns are such a good choice for process development, formulation studies, regulatory filing support, along with ongoing process monitoring as well as quality control."
Avid Bioservices ( Tustin, California ) received early access to the XBridge Premier GTx columns. "The XBridge Premier GTx BEH SEC columns significantly widened the dynamic range of our SEC platform method for AAV aggregate analysis," says Kilian Witzel , Senior Scientist, Analytical Development Viral Vectors, Avid Bioservices, Inc. "It is now possible to analyze AAV aggregates from small amounts of sample with an HPLC method that is up to five times faster than conventional SEC methods for this application. This will help us expedite study timelines and reduce overall costs."
AAVs are modified viruses made in bioreactors by living cells and are the number one vehicle for carrying therapeutic genes into human cells. Waters scientists have developed a fast and efficient multi-attribute quantification method iv of characterizing AAVs that features the following Waters products:
XBridge Premier GTx BEH SEC columns are now available worldwide from Waters.
Additional Resources
About Waters Corporation ( www.waters.com ) Waters Corporation (NYSE: WAT ), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, and food sciences for over 60 years. With approximately 8,000 employees worldwide, Waters operates directly in 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries.
Waters, XBridge, BEH, Wyatt, DAWN, Optilab, Arc, UPLC, and ACQUITY are trademarks of Waters Corporation.
Janice Foley Senior PR Manager, Corporate Communications Waters Corporation [email protected] Mobile: +1.617.823.5555
| i According to beta customer AAV sample analysis and the optimization of lower volume 2.5 µm particle SEC column technology that can produce >3x more concentrated peaks versus an industry standard 7.8 x 300 5 µm particle SEC column. |
| ii As compared to industry-standard, UV-based HPLC methods employing 5 µm silica particles in stainless steel columns limited to measuring aggregation and titer. |
| iii Life Sciences Intelligence , May 24, 2023: "The Top 5 Most Expensive FDA-approved Gene Therapies" |
| iv Method captures the following AAV information: aggregate vs. monomer content, titer, encapsidation ratio, nucleic acid vs. monomer ratio, concentration, absolute molar mass and size, and radii. |